^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunomodulator

    Related drugs:
    22h
    An Open-Label, Double-Treatment Group Study to Evaluate the Efficacy and Safety of Human Allogeneic Bone-Marrow- Derived Mesenchymal Stromal Cell Product StromaForte Compared With Hyaluronic Acid for the Treatment of Knee Osteoarthritis (clinicaltrials.gov)
    P2/3, N=140, Recruiting, Cellcolabs Clinical SPV Limited
    New P2/3 trial
    4d
    Thymalfasin combined with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: A retrospective study on efficacy, safety, and immunological function. (PubMed, Pak J Med Sci)
    Improvements in FACT-L scores were most evident in Group-A (P< 0.05), and declines in 6MWD were smallest in this group(P< 0.05). Thymalfasin combined with ICIs and chemotherapy, particularly platinum-based doublet regimens, may significantly prolong survival, enhance immune function, and improve quality of life in patients with advanced NSCLC, without increasing treatment-related toxicity.
    Retrospective data • Journal • Checkpoint inhibition
    |
    CD4 (CD4 Molecule)
    |
    Zadaxin (thymalfasin)
    6d
    A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty Patients (clinicaltrials.gov)
    P1/2, N=12, Completed, Cellcolabs Clinical SPV Limited | Trial completion date: Apr 2025 --> Aug 2025 | Trial primary completion date: Nov 2024 --> Aug 2025 | Recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    6d
    TAQE: Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma (clinicaltrials.gov)
    P1/2, N=93, Recruiting, VA Office of Research and Development | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    hydroxychloroquine
    6d
    A Study to Evaluate the Safety of Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product StromaForte for the Treatment of Knee Osteoarthritis (clinicaltrials.gov)
    P1/2, N=12, Completed, Cellcolabs Clinical SPV Limited | Recruiting --> Completed
    Trial completion
    6d
    PRAGMATIC: Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial (clinicaltrials.gov)
    P2, N=104, Recruiting, The University of Queensland | Trial completion date: Sep 2026 --> Mar 2027 | Trial primary completion date: Jun 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    7d
    GALPOL: Impact of Ursodeoxycholic Acid Treatment on the Gallbladder Polyp Evolution (clinicaltrials.gov)
    P=N/A, N=36, Active, not recruiting, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Recruiting --> Active, not recruiting | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Feb 2026 --> Apr 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    7d
    ENX-CL-05-002: A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter nStudy of Intra-Articular Allocetra in Participants with Primary Knee nOsteoarthritis. (2025-524668-39-00)
    P1/2, N=75, Not yet recruiting, Enlivex Therapeutics Ltd.
    New P1/2 trial
    |
    Allocetra (HLA-matched donor mononuclear enriched leukocytes)
    8d
    MVX-ONCO-2 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, University Hospital, Geneva | Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2025 --> Nov 2026
    Enrollment closed • Trial primary completion date
    8d
    CASCADES: UNC Cashew Sublingual Immunotherapy (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, University of North Carolina, Chapel Hill | Trial completion date: Feb 2028 --> Dec 2028 | Initiation date: Jan 2026 --> Jun 2026 | Trial primary completion date: Feb 2028 --> Dec 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    8d
    APLAQUINE: Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome (clinicaltrials.gov)
    P2, N=25, Terminated, University Hospital, Rouen | Completed --> Terminated; Difficulty in enrolling new patients
    Trial termination
    |
    hydroxychloroquine
    8d
    A Phase 1 Study of PVT401 in Healthy Subjects (clinicaltrials.gov)
    P1, N=36, Recruiting, Parvus Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human